144 ·Filed Jul 30, 2026

TRDA

Entrada Therapeutics, Inc.
BEARISH
Impact 5/10
Horizondays Processed2mo ago SEC0001674324-26-000006
Actionable Insight ▼ Bearish

Monitor for actual execution of the sale via subsequent Form 4 filings. If 5AM Ventures completes this sale, it could mark the start of a distribution phase, potentially weighing on the stock. Given the stock's historical volatility, traders should watch for further insider selling or additional 144 filings from other affiliates.

DirectionBearish
Confidencemedium
Horizondays
Latest settled — T+20d
TRDA ▲ +3.09% at T+20d
SHORT call ✗ call lost -3.09% · α vs SPY -0.10% · entry $6.79 → $7.00
Next anchor: T+60d in 21d
Latest observation: T+43 -92.58% FF3 residual α
Entry anchored
Jul 30, 03:59 PM ET
via exchange tick
T+1d
+6.92%
call -6.92% · α -5.50%
$7.26
settled 2mo ago
T+5d
+1.18%
call -1.18% · α +2.33%
$6.87
settled 8w ago
T+20d
+3.09%
call -3.09% · α -0.10%
$7.00
settled 5w ago
T+60d
—
call — · α —
—
in 21d

Price Chart

Loading chart...

Executive Summary

5AM Ventures V, L.P., an early venture investor and affiliated stockholder of Entrada Therapeutics, filed a Form 144 notice of intent to sell 331,156 shares of common stock, valued at approximately $2.17 million. The proposed sale represents about 0.85% of shares outstanding and signals potential portfolio distribution by a long-term holder.

Key Facts

  • 5AM Ventures V, L.P. proposes to sell 331,156 shares of Entrada Therapeutics common stock.
  • Estimated market value of the proposed sale is $2,169,072.
  • Shares were acquired on October 12, 2016 via venture financing investment.
  • The sale is to be executed through Goldman Sachs & Co. LLC.
  • Filing date is July 30, 2026; the sale is not yet completed.

Financial Impact

Proposed sale of 331,156 shares (~0.85% of 38.8M shares outstanding) valued at ~$2.17M, representing a modest but notable reduction by a key early investor.

dilutioninsider selling pressure

Risk Factors

  • Further selling by 5AM Ventures or other early investors could increase supply and pressure the stock.
  • The intent-to-sell filing may signal reduced confidence from a long-term holder, potentially spooking retail and institutional investors.
  • Entrada Therapeutics is a small-cap biotech with volatile price action; the sale could amplify downside moves.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (TRDA) — Batch item 10001674324-26-000006
Document: 0001674324-26-000006-index.html0001674324-26-000006
Document: 0001674324-26-000006.txt0001674324-26-000006
144 Filing (TRDA) — Batch item 40001674324-26-000006
Document: 0001674324-26-000006-index.html0001674324-26-000006
Document: 0001674324-26-000006.txt0001674324-26-000006
18 reports for TRDA
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +58.52%May 4, 2026
Filters
Rows
Reports for TRDA — sortable, filterable
TypeNow
Sep 9, 2026
22d ago
Insider Cluster
BEARISH ★ 6/10
$6.42 $6.90▼ −7.48%▼ −7.98%$5.38 (+16.20%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 3/10
$7.17 $6.80▼ −5.16%▼ −4.01%$5.38 (−24.97%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.27 $7.17▼ −1.38%▼ −1.64%$5.38 (−26.00%)
Aug 10, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.04 $7.27▲ +3.27%▲ +3.67%$5.38 (−23.58%)
Aug 5, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$7.06 $7.67▲ +8.64%▲ +8.29%$5.38 (−23.80%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.24 $7.04▼ −2.76%▼ −2.66%$5.38 (−25.69%)
Jul 30, 2026
9w ago
144
BEARISH ★ 5/10
$6.79 $6.87▼ −1.18%▲ +2.33%$5.38 (+20.77%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access